Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.
Saved in:
| Title: | Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors. |
|---|---|
| Authors: | Sommer A; Bayer Pharma AG, Berlin, Germany. anette.sommer@bayer.com., Kopitz C; Bayer Pharma AG, Berlin, Germany., Schatz CA; Bayer Pharma AG, Berlin, Germany., Nising CF; Bayer Pharma AG, Wuppertal, Germany., Mahlert C; Bayer Pharma AG, Wuppertal, Germany., Lerchen HG; Bayer Pharma AG, Wuppertal, Germany., Stelte-Ludwig B; Bayer Pharma AG, Wuppertal, Germany., Hammer S; Bayer Pharma AG, Berlin, Germany., Greven S; Bayer Pharma AG, Wuppertal, Germany., Schuhmacher J; Bayer Pharma AG, Wuppertal, Germany., Braun M; Bayer Pharma AG, Berlin, Germany., Zierz R; Bayer Pharma AG, Berlin, Germany., Wittemer-Rump S; Bayer Pharma AG, Berlin, Germany., Harrenga A; Bayer Intellectual Property GmbH, Monheim, Germany., Dittmer F; Bayer Pharma AG, Wuppertal, Germany., Reetz F; Bayer Pharma AG, Berlin, Germany., Apeler H; Bayer Pharma AG, Wuppertal, Germany., Jautelat R; Bayer Pharma AG, Wuppertal, Germany., Huynh H; National Cancer Center Singapore, Division of Cellular & Molecular Research, Singapore., Ziegelbauer K; Bayer Pharma AG, Berlin, Germany., Kreft B; Bayer Pharma AG, Berlin, Germany. |
| Source: | Cancer research [Cancer Res] 2016 Nov 01; Vol. 76 (21), pp. 6331-6339. Date of Electronic Publication: 2016 Aug 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 2984705R Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1538-7445 (Electronic) Linking ISSN: 00085472 NLM ISO Abbreviation: Cancer Res Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
